<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03591874</url>
  </required_header>
  <id_info>
    <org_study_id>OCU-300-301</org_study_id>
    <nct_id>NCT03591874</nct_id>
  </id_info>
  <brief_title>Study of Brimonidine Tartrate Nanoemulsion Eye Drops in Patients With Ocular Graft-vs-Host Disease</brief_title>
  <acronym>oGVHD</acronym>
  <official_title>A Phase 3 Randomized, Placebo-Controlled, Double-Masked, Multicenter, Safety and Efficacy Study of Brimonidine Tartrate Nanoemulsion Eye Drops in Patients With Ocular Graft-vs-Host Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ocugen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ocugen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the use of Brimonidine tartrate nanoemulsion eye drop solution in the
      treatment of ocular Graft Verses Host Disease (oGVHD). Two thirds of participants will
      receive Brimonidine and one third will receive ophthalmic buffered saline (placebo).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ocular GVHD (oGVHD) is a common complication that occurs in 40-60% of patients who have
      undergone allogeneic bone marrow transplants. Driven by inflammation, oGVHD can result in
      damage to the ocular surface and tear-producing glands, which over time significantly
      diminishes quality of life and restricts daily activities due to visual impairment.

      Early studies in animals and humans indicate that Brimonidine nano-emulsion, also known as
      OCU300, may relieve the signs and symptoms of oGVHD. These symptoms include blurry vision,
      foreign body sensation, burning sensation, severe light sensitivity, chronic conjunctivitis
      (pink or red eye), dry eyes and eye pain.

      This study will be a randomized, placebo-controlled, double-masked, multicenter phase 3 study
      in the United States conducted at approximately 15 centers. Upon meeting the eligibility
      criteria, enrolled subjects with a diagnosis of definite oGVHD will be randomly assigned in a
      2:1 (test: control) fashion to receive either Brimonidine Nanoemulsion Eye Drops 0.18%
      investigational product (test) or ophthalmic buffered saline (placebo).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 23, 2018</start_date>
  <completion_date type="Actual">June 28, 2020</completion_date>
  <primary_completion_date type="Actual">June 15, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This will be a randomized, placebo-controlled, double-masked, multicenter phase 3 study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>All subjects, investigators, and study personnel involved in the conduct of the study, including data management and statistics, will be masked to treatment assignment except for a specified staff member from the designated packaging vendor who will do the package labeling.
Unmasking will be permitted in a medical emergency that requires immediate knowledge of the subject's treatment assignment.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Validated Bulbar Redness (VBR)</measure>
    <time_frame>Between baseline and 12 weeks of treatment</time_frame>
    <description>Ocular redness based on a 100-point scale measuring change in appearance.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>10-point Visual Analog Scale (VAS)</measure>
    <time_frame>Between baseline and 12 weeks of treatment</time_frame>
    <description>Measured change in Ocular discomfort intensity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dry Eye (SANDE) questionnaire</measure>
    <time_frame>Between baseline and 12 weeks of treatment</time_frame>
    <description>Change in Symptom Assessment scores</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Validated Bulbar Redness (VBR) score</measure>
    <time_frame>At days 28 and 56</time_frame>
    <description>Change from baseline</description>
  </other_outcome>
  <other_outcome>
    <measure>Ocular Discomfort Score</measure>
    <time_frame>At days 28 and 56</time_frame>
    <description>Change from baseline</description>
  </other_outcome>
  <other_outcome>
    <measure>Ocular Surface Disease Index (OSDI)</measure>
    <time_frame>At 12 weeks (Day 84)</time_frame>
    <description>Change from baseline</description>
  </other_outcome>
  <other_outcome>
    <measure>Corneal fluorescein staining (NEI score)</measure>
    <time_frame>At 12 weeks (Day 84)</time_frame>
    <description>Change from baseline</description>
  </other_outcome>
  <other_outcome>
    <measure>Corneal Lissamine Green (LG) staining (NEI Scale)</measure>
    <time_frame>At 12 weeks (Day 84)</time_frame>
    <description>Change from baseline</description>
  </other_outcome>
  <other_outcome>
    <measure>Conjunctival lissamine green (LG) staining (NEI Scale)</measure>
    <time_frame>At 12 weeks (Day 84)</time_frame>
    <description>Change from baseline</description>
  </other_outcome>
  <other_outcome>
    <measure>Tear secretion as measured by Schirmer's test</measure>
    <time_frame>At 12 weeks (Day 84)</time_frame>
    <description>Change from baseline</description>
  </other_outcome>
  <other_outcome>
    <measure>Clinical global impression of change in signs and symptoms (Physician's rating)</measure>
    <time_frame>At 12 weeks (Day 84)</time_frame>
    <description>Change from baseline</description>
  </other_outcome>
  <other_outcome>
    <measure>Subject global assessment of overall change (Subject's rating)</measure>
    <time_frame>At 12 weeks (Day 84)</time_frame>
    <description>Change from baseline</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Graft Versus Host Disease</condition>
  <condition>Ocular Surface Disease</condition>
  <condition>oGVHD</condition>
  <condition>Ocular Graft vs Host Disease</condition>
  <condition>Brimonidine Tartrate</condition>
  <condition>Lubricant Eye Drops</condition>
  <condition>Ophthalmic Solutions</condition>
  <condition>Graft vs Host Disease</condition>
  <arm_group>
    <arm_group_label>OCU-300</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Brimonidine Tartrate Nanoemulsion Eye Drops 0.18% given 2 times a day for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebos</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo - Ophthalmic buffered saline Eye Drops given 2 times a day for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brimonidine Tartrate</intervention_name>
    <description>Brimonidine Tartrate Nanoemulsion Eye Drops given 2 times a day for 12 weeks.</description>
    <arm_group_label>OCU-300</arm_group_label>
    <other_name>OCU-300</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Opthalmic buffered saline solution Eye Drops given 2 times a day for 12 weeks.</description>
    <arm_group_label>Placebos</arm_group_label>
    <other_name>Placebo (For Brimonidine Tartrate)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or women ≥ 18 years of age

          -  Diagnosis of definite oGVHD using the International Chronic Ocular GVHD Consensus
             Group Revised Diagnostic criteria in at least one eye.

          -  Ocular Discomfort score ≥ 3

          -  Validated Bulbar Redness score ≥ 40 in both eyes

          -  Subjects who are capable and willing to provide informed consent and follow study
             instructions

          -  Intraocular pressure (IOP) ≥ 5 mmHg and ≤22 mmHg in each eye

          -  Women who are not pregnant or lactating or post-menopausal or have undergone a
             sterilization procedure

        Exclusion Criteria:

          -  Allergic to brimonidine or any similar products, or excipients of brimonidine

          -  Currently receiving any brimonidine or other treatment for glaucoma

          -  Receiving or have received any investigational drug or device within 30 days of
             screening

          -  Current use of contact lenses 14 days prior to screening

          -  Active ocular infection or ocular allergies

          -  Any history of eyelid surgery or ocular surgery within the past 3 months

          -  Corneal epithelial defect larger than 1 mm (squared) in either eye

          -  Received corticosteroid-containing eye drops within 14 days prior to screening or
             planned use during the study

          -  Any change in corticosteroid-containing eye drops, systemic
             corticosteroids/immunosuppressives, topical ocular antibiotics, cyclosporine
             ophthalmic emulsion 0.05% (Restasis®), cyclosporine ophthalmic solution 0.09% (Cequa®)
             or lifitegrast ophthalmic solution 5% (Xiidra®), or autologous serum tears within 30
             days prior to screening or planned change during the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward J Walters, MPH</last_name>
    <role>Study Director</role>
    <affiliation>Ocugen, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Byers Eye Institute at Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory Eye Center</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Prairie Village</city>
        <state>Kansas</state>
        <zip>66208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan, Kellogg Eye Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OHSU Casey Eye Institute | Cornea Division</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Penn Scheie Eye Institute,</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univeristy of Pittsburgh Medical Center Eye Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Dept. of Ophthalmology and Visual Sciences</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>July 9, 2018</study_first_submitted>
  <study_first_submitted_qc>July 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 19, 2018</study_first_posted>
  <last_update_submitted>June 30, 2020</last_update_submitted>
  <last_update_submitted_qc>June 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ogvhd</keyword>
  <keyword>ocular graft vs host</keyword>
  <keyword>Ocular Surface Disease</keyword>
  <keyword>Ocular Graft vs Host Disease</keyword>
  <keyword>Brimonidine Tartrate</keyword>
  <keyword>Lubricant Eye Drops</keyword>
  <keyword>Ophthalmic Solutions</keyword>
  <keyword>Graft vs Host Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brimonidine Tartrate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>There is no current plan to share participant data with other researchers.</ipd_description>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>A clinical Study Report will be submitted once the study data has been analyzed.</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

